rAdp53

rAdp53 (recombinant human adenovirus p53) is a gene therapy product that uses a replication-defective adenoviral vector to deliver the wild-type TP53 tumor suppressor gene into tumor cells. The primary mechanism of action is restoration of functional p53 protein in cancer cells with mutated or inactivated endogenous TP53. This leads to cell cycle arrest and induction of apoptosis through transcriptional activation of downstream targets such as p21 and pro-apoptotic genes (e.g., BAX), inhibition of angiogenesis via downregulation of VEGF, and enhancement of sensitivity to chemotherapy and radiotherapy. The therapy does not integrate into the host genome but transiently expresses the delivered gene. It was developed primarily for cancer indications where loss or mutation of TP53 drives malignancy[3][4].

Brand names

Gendicine

Other names

recombinant human adenovirus p53recombinant adenovirus-p53 gene therapy